RT Journal Article
SR Electronic
T1 GWAS defines pathogenic signaling pathways and prioritizes drug targets for IgA nephropathy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21265383
DO 10.1101/2021.11.19.21265383
A1 Kiryluk, Krzysztof
A1 Sanchez-Rodriguez, Elena
A1 Zhou, Xu-jie
A1 Zanoni, Francesca
A1 Liu, Lili
A1 Mladkova, Nikol
A1 Khan, Atlas
A1 Marasa, Maddalena
A1 Zhang, Jun Y.
A1 Balderes, Olivia
A1 Sanna-Cherchi, Simone
A1 Bomback, Andrew S.
A1 Canetta, Pietro A.
A1 Appel, Gerald B.
A1 Radhakrishnan, Jai
A1 Trimarchi, Hernan
A1 Sprangers, Ben
A1 Cattran, Daniel C.
A1 Reich, Heather
A1 Pei, York
A1 Ravani, Pietro
A1 Galesic, Kresimir
A1 Maixnerova, Dita
A1 Tesar, Vladimir
A1 Stengel, Benedicte
A1 Metzger, Marie
A1 Canaud, Guillaume
A1 Maillard, Nicolas
A1 Berthoux, Francois
A1 Berthelot, Laureline
A1 Pillebout, Evangeline
A1 Monteiro, Renato
A1 Nelson, Raoul
A1 Wyatt, Robert
A1 Smoyer, William
A1 Mahan, John
A1 Samhar, Al-Akash
A1 Hidalgo, Guillermo
A1 Quiroga, Alejandro
A1 Weng, Patricia
A1 Sreedharan, Raji
A1 Selewski, David
A1 Davis, Keefe
A1 Kallash, Mahmoud
A1 Vasylyeva, Tetyana L.
A1 Rheault, Michelle
A1 Chishti, Aftab
A1 Ranch, Daniel
A1 Wenderfer, Scott E.
A1 Samsonov, Dmitry
A1 Claes, Donna J.
A1 Oleh, Akchurin
A1 Goumenos, Dimitrios
A1 Stangou, Maria
A1 Nagy, Judit
A1 Kovacs, Tibor
A1 Fiaccadori, Enrico
A1 Amoroso, Antonio
A1 Barlassina, Cristina
A1 Cusi, Daniele
A1 Vecchio, Lucia Del
A1 Battaglia, Giovanni Giorgio
A1 Bodria, Monica
A1 Boer, Emanuela
A1 Bono, Luisa
A1 Boscutti, Giuliano
A1 Caridi, Gianluca
A1 Lugani, Francesca
A1 Ghiggeri, GianMarco
A1 Coppo, Rosanna
A1 Peruzzi, Licia
A1 Esposito, Vittoria
A1 Esposito, Ciro
A1 Feriozzi, Sandro
A1 Polci, Rosaria
A1 Frasca, Giovanni
A1 Galliani, Marco
A1 Garozzo, Maurizio
A1 Mitrotti, Adele
A1 Gesualdo, Loreto
A1 Granata, Simona
A1 Zaza, Gianluigi
A1 Londrino, Francesco
A1 Magistroni, Riccardo
A1 Pisani, Isabella
A1 Magnano, Andrea
A1 Marcantoni, Carmelita
A1 Messa, Piergiorgio
A1 Mignani, Renzo
A1 Pani, Antonello
A1 Ponticelli, Claudio
A1 Roccatello, Dario
A1 Salvadori, Maurizio
A1 Salvi, Erica
A1 Santoro, Domenico
A1 Gembillo, Guido
A1 Savoldi, Silvana
A1 Spotti, Donatella
A1 Zamboli, Pasquale
A1 Izzi, Claudia
A1 Alberici, Federico
A1 Delbarba, Elisa
A1 Florczak, Michał
A1 Krata, Natalia
A1 Mucha, Krzysztof
A1 Pączek, Leszek
A1 Niemczyk, Stanisław
A1 Moszczuk, Barbara
A1 Pańczyk-Tomaszewska, Malgorzata
A1 Mizerska-Wasiak, Malgorzata
A1 Perkowska-Ptasińska, Agnieszka
A1 Bączkowska, Teresa
A1 Durlik, Magdalena
A1 Pawlaczyk, Krzysztof
A1 Sikora, Przemyslaw
A1 Zaniew, Marcin
A1 Kaminska, Dorota
A1 Krajewska, Magdalena
A1 Kuzmiuk-Glembin, Izabella
A1 Heleniak, Zbigniew
A1 Bullo-Piontecka, Barbara
A1 Liberek, Tomasz
A1 Dębska-Slizien, Alicja
A1 Hryszko, Tomasz
A1 Materna-Kiryluk, Anna
A1 Miklaszewska, Monika
A1 Szczepańska, Maria
A1 Dyga, Katarzyna
A1 Machura, Edyta
A1 Siniewicz-Luzeńczyk, Katarzyna
A1 Pawlak-Bratkowska, Monika
A1 Tkaczyk, Marcin
A1 Runowski, Dariusz
A1 Kwella, Norbert
A1 Drożdż, Dorota
A1 Habura, Ireneusz
A1 Kronenberg, Florian
A1 Prikhodina, Larisa
A1 van Heel, David
A1 Fontaine, Bertrand
A1 Cotsapas, Chris
A1 Wijmenga, Cisca
A1 Franke, Andre
A1 Annese, Vito
A1 Gregersen, Peter K.
A1 Parameswaran, Sreeja
A1 Weirauch, Matthew
A1 Kottyan, Leah
A1 Harley, John B
A1 Suzuki, Hitoshi
A1 Narita, Ichiei
A1 Goto, Shin
A1 Lee, Hajeong
A1 Kim, Dong Ki
A1 Kim, Yon Su
A1 Park, Jin-Ho
A1 Cho, BeLong
A1 Choi, Murim
A1 Van Wijk, Ans
A1 Huerta, Ana
A1 Ars, Elisabet
A1 Ballarin, Jose
A1 Lundberg, Sigrid
A1 Vogt, Bruno
A1 Mani, Laila-Yasmin
A1 Caliskan, Yasar
A1 Barratt, Jonathan
A1 Abeygunaratne, Thilini
A1 Kalra, Philip A.
A1 Gale, Daniel P.
A1 Panzer, Ulf
A1 Rauen, Thomas
A1 Floege, Jürgen
A1 Schlosser, Pascal
A1 Ekici, Arif B.
A1 Eckardt, Kai-Uwe
A1 Chen, Nan
A1 Xie, Jingyuan
A1 Lifton, Richard P.
A1 Loos, Ruth J. F.
A1 Kenny, Eimear E.
A1 Ionita-Laza, Iuliana
A1 Köttgen, Anna
A1 Julian, Bruce
A1 Novak, Jan
A1 Scolari, Francesco
A1 Zhang, Hong
A1 Gharavi, Ali G.
YR 2021
UL http://medrxiv.org/content/early/2021/11/20/2021.11.19.21265383.abstract
AB IgA nephropathy (IgAN) is a progressive form of kidney disease defined by glomerular deposition of IgA. We performed a genome-wide association study involving 10,146 kidney biopsy-diagnosed IgAN cases and 28,751 matched controls across 17 international cohorts. We defined 30 independent genome-wide significant risk loci jointly explaining 11% of disease risk. A total of 16 loci were novel, including TNFSF4, REL, CD28, CXCL8/PF4V1, LY86, LYN, ANXA3, TNFSF8/15, REEP3, ZMIZ1, RELA, ETS1, IGH, IRF8, TNFRSF13B and FCAR. The SNP-based heritability of IgAN was estimated at 23%. We observed a positive genetic correlation between IgAN and total serum IgA levels, allergy, tonsillectomy, and several infections, and a negative correlation with inflammatory bowel disease. All significant non-HLA loci shared with serum IgA levels had a concordant effect on the risk of IgAN. Moreover, IgAN loci were globally enriched in gene orthologs causing abnormal IgA levels when genetically manipulated in mice. The explained heritability was enriched in the regulatory elements of cells from the immune and hematopoietic systems and intestinal mucosa, providing support for the pathogenic role of extra-renal tissues. The polygenic risk of IgAN was associated with early disease onset, increased lifetime risk of kidney failure, as well as hematuria and several other traits in a phenome-wide association study of 590,515 individuals. In the comprehensive functional annotation analysis of candidate causal genes across genome-wide significant loci, we observed the convergence of biological candidates on a common set of inflammatory signaling pathways and cytokine ligand-receptor pairs, prioritizing potential new drug targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was founded by Columbia University, Columbia Glomerular Center, IGA Nephropathy Foundation of America, and National Institute for Diabetes and Digestive Kidney Diseases (NIDDK) grants R01DK105124 and RC2DK116690, R01DK082753. Additional support was provided by R01LM013061, U01HG008680, U01AI152960, R01DK078244, R01AI149431, National Science Foundation of China (82022010, 82070733); Beijing Natural Science Foundation (Z190023); DFG Project ID 192904750 CRC 992 Medical Epigenetics, DFG Project ID 431984000 CRC 1453, and the EQUIP Program for Medical Scientists, Faculty of Medicine, University of Freiburg. JBH, SP, KL, and WM were supported by R01HG010730, U01AI130830, R01NS099068, R01AI024717, R01AR073228, U01AI150748, R01AI148276, P01AI150585 and the US Department of Veterans Affairs Merit Award I01BX001834 to JBH. DPG was supported by the St Peter's Trust for Kidney, Bladder and Prostate Research. The UK cohort data was generated as a result of a grant from Kidney Research UK and the Medical Research Council (JB and DG). The German STOP-IgAN study was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) CRU 5011 and Project ID 445703531. The GCKD (German Chronic Kidney Disease) study was funded by grants from the German Ministry of Education and Research (BMBF, No. 01ER0804) and the KfH Foundation for Preventive Medicine.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All subjects provided informed consent to participate in genetic studies, and the Institutional Review Board (IRB) of Columbia University as well as local ethics review committees for each of the individual cohorts approved our study protocol.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.